Biogen Inc.
BIIB
Kedudukan dalam Saham
#681
Biogen Inc. is a leading biotechnology firm dedicated to the discovery,... Biogen Inc. is a leading biotechnology firm dedicated to the discovery, development, production, and distribution of treatments for complex neurological and neurodegenerative conditions. Its established portfolio includes a range of medications addressing multiple sclerosis (MS), such as TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA. For spinal muscular atrophy (SMA), Biogen provides SPINRAZA, while FUMADERM is available for the treatment of plaque psoriasis. Among its other key offerings is ADUHELM, specifically developed for Alzheimer's disease. The company also markets a selection of biosimilar drugs, including BENEPALI (an etanercept biosimilar akin to ENBREL), IMRALDI (an adalimumab biosimilar comparable to HUMIRA), and FLIXABI (an infliximab biosimilar referencing REMICADE). Further extending its therapeutic reach, Biogen supplies RITUXAN, prescribed for conditions like non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, certain types of ANCA-associated vasculitis, and pemphigus vulgaris. RITUXAN HYCELA targets non-Hodgkin's lymphoma and CLL, and GAZYVA is utilized for CLL and follicular lymphoma. OCREVUS addresses both relapsing and primary progressive forms of MS, complementing the company's broader efforts in anti-CD20 therapies. The company maintains a robust research and development pipeline, featuring numerous investigational therapies. These candidates are designed to tackle a wide spectrum of conditions, including multiple sclerosis and neuroimmunological disorders (e.g., BIIB135, BIIB061, BIIB091, BIIB107), Alzheimer's disease and other forms of dementia (e.g., Aducanumab, Lecanemab, BIIB076, BIIB080), neuromuscular disorders (e.g., BIIB067, BIIB078, BIIB105, BIIB100, BIIB110), Parkinson's disease and related movement disorders (e.g., BIIB124, BIIB094, BIIB118, BIIB101, BIIB122), neuropsychiatric conditions (e.g., BIIB125, BIIB104), immunology-related illnesses (e.g., Dapirolizumab pegol, BIIB059), acute neurological events (e.g., BIIB093, BIIB131), and neuropathic pain (e.g., BIIB074). Additionally, several biosimilar candidates, such as BYOOVIZ, BIIB800, and SB15, are progressing through various developmental stages. Biogen actively engages in strategic collaborations and licensing arrangements with various partners, including Acorda Therapeutics, Inc., Alkermes Pharma Ireland Limited, Denali Therapeutics Inc., Eisai Co., Ltd., Genentech, Inc., Neurimmune SubOne AG, Ionis Pharmaceuticals, Inc., Samsung Bioepis Co., Ltd., Sangamo Therapeutics, Inc., and Sage Therapeutics, Inc. Established in 1978, Biogen Inc. maintains its corporate headquarters in Cambridge, Massachusetts.
Harga Saham
$242.79
Modal Pasaran
$35.87B
Perubahan (1 hari)
3.99%
Perubahan (1 tahun)
65.58%
Negara
US
Perdagangan Biogen Inc. (BIIB)
Kategori
Healthcare
Bilangan saham terbitan bagi Biogen Inc. (BIIB)
Bilangan saham terbitan setakat June 2026: 147.70M
Menurut laporan kewangan terkini dan harga saham Biogen Inc., bilangan saham terbitan semasa ialah 147.70M. Pada akhir December 2024, syarikat mempunyai 145.70M saham terbitan. Bilangan saham terbitan biasanya dipengaruhi oleh pecahan saham dan pembelian balik saham.
Sejarah saham terbitan untuk Biogen Inc. (BIIB) dari 2000 hingga 2026
Saham terbitan pada akhir setiap tahun
| Tahun | Saham Terbitan | Ubah |
|---|---|---|
| 2026 (TTM) | 147.70M | 0.68% |
| 2025 | 146.70M | 0.69% |
| 2024 | 145.70M | 0.69% |
| 2023 | 144.70M | -0.41% |
| 2022 | 145.30M | -2.55% |
| 2021 | 149.10M | -7.33% |
| 2020 | 160.90M | -14.00% |
| 2019 | 187.10M | -8.69% |
| 2018 | 204.90M | -3.62% |
| 2017 | 212.60M | -2.66% |
| 2016 | 218.40M | -5.33% |
| 2015 | 230.70M | -2.39% |
| 2014 | 236.36M | -0.24% |
| 2013 | 236.92M | -0.43% |
| 2012 | 237.94M | -1.84% |
| 2011 | 242.40M | -3.93% |
| 2010 | 252.31M | -12.20% |
| 2009 | 287.36M | -1.70% |
| 2008 | 292.33M | -7.44% |
| 2007 | 315.84M | -6.72% |
| 2006 | 338.59M | 0.89% |
| 2005 | 335.59M | 0.18% |
| 2004 | 335.00M | 0.39% |
| 2003 | 333.70M | -14.43% |
| 2002 | 389.96M | 0.00% |
| 2001 | 389.96M | -12.61% |
| 2000 | 446.23M | 0.00% |
Saham terbitan bagi syarikat atau pesaing yang serupa
| Syarikat | Saham Terbitan | Perbezaan | Negara |
|---|---|---|---|
| 892.40M | 504.20% |
US
|
|
| 2.45B | 1,557.11% |
US
|
|
| 1.77B | 1,099.05% |
US
|
|
| 0.00 | -100.00% |
US
|
|
| 796.00M | 438.93% |
CH
|
